Early Access to Medicines Scheme
Merck’s targeted lung cancer drug tepotinib wins early access in UK
BI drug named Promising Innovative Medicine in mesothelioma
Patients to get Santhera’s Raxone under EAMS scheme.
UK patients gain early access to Duchenne drug